BRIEF-FDA Approves Pembrolizumab With Chemotherapy For Unresectable Advanced Or Metastatic Malignant Pleural Mesothelioma-February 2024-www.financetom.com

BRIEF-FDA Approves Pembrolizumab With Chemotherapy For Unresectable Advanced Or Metastatic Malignant Pleural Mesothelioma

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-FDA Approves Pembrolizumab With Chemotherapy For Unresectable Advanced Or Metastatic Malignant Pleural Mesothelioma

Sep 20, 2024 10:33 PM

Sept 17 (Reuters) - U.S. Food and Drug Administration

(FDA):

* FDA APPROVES PEMBROLIZUMAB WITH CHEMOTHERAPY FOR

UNRESECTABLE

ADVANCED OR METASTATIC MALIGNANT PLEURAL MESOTHELIOMA

Further company coverage:

([email protected])

Previous page： --MFA Financial Keeps Quarterly Cash Dividend at $0.35 a Share, Payable Oct. 31 to Shareholders of Record Sept. 27 Next page： First Quantum expects feasibility studies for Peru mine by 2028, manager says

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--MFA Financial Keeps Quarterly Cash Dividend at $0.35 a Share, Payable Oct. 31 to Shareholders of Record Sept. 27

Sep 13, 2024

04:52 PM EDT, 09/12/2024 (MT Newswires) -- Price: 12.88, Change: +0.19, Percent Change: +1.50 ...

First Quantum expects feasibility studies for Peru mine by 2028, manager says

Sep 13, 2024

LIMA, Sept 12 (Reuters) - Canadian miner First Quantum Minerals ( FQVLF ) expects updated drilling results for its Peru copper project La Granja in the second half of next year, and feasibility studies by 2028, project development manager Steven Lewis said on Thursday. The drilling is progressing well, it's at 35%, and we expect to have the results in...

Day One Biopharmaceuticals Insider Sold Shares Worth $426,675, According to a Recent SEC Filing

Sep 13, 2024

04:52 PM EDT, 09/12/2024 (MT Newswires) -- Samuel C. Blackman, Head of R&D, on September 10, 2024, sold 30,000 shares in Day One Biopharmaceuticals ( DAWN ) for $426,675. Following the Form 4 filing with the SEC, Blackman has control over a total of 2,097,535 shares of the company, with 1,097,535 shares held directly and 1,000,000 controlled indirectly. SEC Filing:...

Ampco-Pittsburgh Unit Gets $8.7 Million Order

Sep 13, 2024

04:54 PM EDT, 09/12/2024 (MT Newswires) -- Ampco-Pittsburgh ( AP ) said its Air and Liquid Systems unit received an $8.7 million order for a custom air handling project for an undisclosed major pharmaceutical company. The order is expected to ship next year, Ampco-Pittsburgh ( AP ) said Thursday in a statement. Ampco-Pittsburgh ( AP ) shares fell 7.7% in...